4507:TYO
Shionogi & Co Ltd
Â¥2,939.00
arrow_upward
+0.17%(+5.00) 1D
Oct 19, 3:30:00 PM GMT+9 · JPY
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4507...
Open
Â¥2,963
High
Â¥2,974
Low
Â¥2,919
Mkt. cap
2.61T
Avg. vol.
3.20M
Volume
2.07M
Dividend
2.42%
Quarterly dividend
Â¥18
Ex-dividend date
Sep 29, 2026
P/E ratio
9.49
52-wk high
Â¥3,758
52-wk low
Â¥2,402
EPS
Â¥310
Shares outstanding
314.50M
No. of employees
6K
Open
Â¥2,963
High
Â¥2,974
Low
Â¥2,919
Mkt. cap
2.61T
Avg. vol.
3.20M
Volume
2.07M
Dividend
2.42%
Quarterly dividend
Â¥18
Ex-dividend date
Sep 29, 2026
P/E ratio
9.49
52-wk high
Â¥3,758
52-wk low
Â¥2,402
EPS
Â¥310
Shares outstanding
314.50M
No. of employees
6K
News stories
From web sources and news partners
Bloomberg
·
15 minutes ago
US Stock Futures Edge Higher After Chipmaker Rally: Markets Wrap
TradingView
·
14 minutes ago
Nasdaq Jumps Past 1 Percent as VIX Swings While Dow Dips Below Its 50-Day Line
BBN Times
·
39 minutes ago
S&P 500 Rises to 7,690.73 as Tech and AI Stocks Rebound From Worst Week Since June Amid US-Iran Negotiations
Investing.com
·
1 hour ago
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.07%
Profile
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana.
Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.
In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan.
Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.
The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.
In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m.
On 5 October 2026, Shionogi announced an agreement to acquire IntraBio for US$2 billion through its US subsidiary, Shionogi Inc. Wikipedia
About Shionogi & Co Ltd
CEOIsao Teshirogi
Employees6.22K
Founded1878
Headquarters-
SectorPharmaceutical industry
Websiteshionogi.com